Ea5182- Osimertinib With Or Without Bevacizumab As Initial Treatment For Patients With Egfr-Mutant Lung Cancer
Posted Date: May 13, 2021
- Investigator: Christopher Lemmon
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The main purpose of this study is to compare the effect of bevacizumab and AZD9291 (osimertinib) combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The primary outcome measured will be progression free survival.
Criteria:
Must Have Pathologically-Confirmed Diagnosis Of Advanced Non-Squamous, Non-Small Cell Lung Cancer (Nsclc), Ecog 0-2, Adequate Organ Function Per Protocol, Hiv/Hbv/Hcv Must Have Undetectable Viral Load, No Prior Treatment With An Egfr Tki Or With An Anti-
Keywords:
Lung Cancer, Nsclc
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com